Series A25 July 2024

4D Medicine secures £3.4m Series A funding to advance pre-clinical testing and US market entry

Oshen Holdings led the Series A round with backing from DSW Ventures, SFC Capital, and Boundary Capital.

£3.4MSeries A

4D Medicine is a UK-based business that has created a resorbable biomaterial for 3D printed surgical devices and implants. The enterprise operates out of Nottingham with its own development and production facility.

4D Medicine has secured £3.4m in a Series A financing round led by Oshen Holdings. The capital injection also drew participation from DSW Ventures, SFC Capital, Boundary Capital, and various private investors including medical professionals.

The proceeds will be directed towards finalising pre-clinical trials for the company initial product line and pursuing regulatory clearance from the FDA to enter the American market. This latest raise brings the company total funding to date to £5m as it prepares for a subsequent Series B round early next year.

The business originates as a spin-out from the Universities of Birmingham and Warwick, having developed a proprietary polycarbonate-urethane resin known as 4Degra. This material gradually erodes through normal metabolic processes as natural tissue regenerates, avoiding the acidic by-products associated with older resorbable polymers.

From the founder

"I would like to thank all our investors for their trust and support. Our success in continuing to raise investment despite the difficult market conditions over the last few years is testament to their belief in the company’s commercial potential and our world-class team. The funds will be used to complete the pre-clinical testing of our first medical device product range and our preparations for entry into the orthopaedic market."

Philip Smith

CEO at 4D Medicine

Investor perspective

"We were delighted to lead this deal and we look forward to working with the 4D team. The company is now poised to make a substantial impact in the bioresorbable medical device space. We believe that 4Degra is a real game-changer that is enabling 4D to develop novel bioresorbable medical devices with unique properties."

Didier Cowling

Partner, Oshen Holdings